Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users

被引:15
|
作者
Jamalidoust, Marzieh [1 ]
Namayandeh, Mandana [1 ]
Moghadami, Mohsen [1 ]
Ziyaeyan, Mazyar [1 ]
机构
[1] Shiraz Univ Med Sci, Nemazi Hosp, Prof Alborzi Clin Microbiol Res Ctr, Dept Virol, POB 31, Shiraz 7193711351, Iran
来源
VIROLOGY JOURNAL | 2017年 / 14卷
关键词
Hepatitis C virus; HIV; HCV genotypes; Illicit drug users; Quantitative PCR assay; HUMAN-IMMUNODEFICIENCY-VIRUS; CHRONIC HEPATITIS-C; INTERFERON-PLUS-RIBAVIRIN; CLINICAL-OUTCOMES; COINFECTION; HIV; COHORT; PREVALENCE; METAANALYSIS; PROGRESSION;
D O I
10.1186/s12985-017-0797-2
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Because of shared modes of transmission, patients with hepatitis C virus (HCV) infection are often co-infected with other types of hepatitis viruses and/or HIV. We studied HCV viral load and its genotype patterns among HCV mono-and HCV/HIV co-infected Illicit Drug Users in Fars province-Iran. Methods: Totally, 580 HCV seropositive IDUs referred to Prof. Alborzi Clinical Microbiology Research Center, Shiraz, Iran, without receiving any anti-HCV treatment, were enrolled. After their HCV infections were reconfirmed by one step rapid diagnostic test, HCV RNA level and HCV genotypes were determined by Taq-man real-time PCR assays. Their HIV serostatus was determined and seropositive patients were excluded from the group. In addition, 104 HIV/HCV co-infected IDUs referred from Shiraz Behavioral Diseases Consultation Center (SBDC) were assessed for HCV RNA level and HCV genotype patterns, as well. Results: The overall estimated HIV prevalence was 6.7% (39/580) among HCV seropositive IDUs. Genotype 1, the most prevalent genotype in both groups, was detected in 69% and 49% of co- and mono-infected IDUs, respectively. Median HCV viral load was significantly higher in HIV/HCV co-infected patients, compared with that among HCV mono-infected counterparts. Conclusions: Given the higher baseline HCV viral load and GT1 attributed to poorer treatments response, HCV treatment must be more considered among HCV/HIV co-infected IDUs, compared to those mono-infected with HCV.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Linkage Outcomes for HIV/HCV Co-Infected and HCV Mono-Infected Patients Participating in an Emergency Department Screening Program
    Cowan, E.
    Hardardt, J.
    Brandspiegel, S.
    Calderon, Y.
    ANNALS OF EMERGENCY MEDICINE, 2020, 76 (04) : S49 - S49
  • [42] Different impact of DAA on innate and adaptive cellular immunity in HIV/HCV co-infected and HCV mono-infected patients
    Zuccala, Paola
    Lichtner, Miriam
    Vita, Serena
    Marocco, Raffaella
    Mascia, Claudia
    Savinelli, Stefano
    Campagna, Michela
    Mengoni, Fabio
    Tieghi, Tiziana
    Pozzetto, Irene
    D'Ettorre, Gabriella
    Paoletti, Francesca
    Mastroianni, Claudio Maria
    Vullo, Vincenzo
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [43] MicroRNA signature from extracellular vesicles of HCV/HIV co-infected individuals differs from HCV mono-infected
    Cairoli, Victoria
    Valle-Millares, Daniel
    Terron-Orellano, Maria C.
    Luque, Daniel
    Ryan, Pablo
    Dominguez, Lourdes
    Martin-Carbonero, Luz
    De los Santos, Ignacio
    De Matteo, Elena
    Ameigeiras, Beatriz
    Briz, Veronica
    Casciato, Paola
    Preciado, Maria Victoria
    Valva, Pamela
    Fernandez-Rodriguez, Amanda
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2023, 101 (11): : 1409 - 1420
  • [44] Quality of life, symptomatology and healthcare utilization in HIV/HCV co-infected drug users in Miami
    Baum, Marianna K.
    Jayaweera, Dushyantha T.
    Duan, Rui
    Sales, Sabrina
    Lai, Shenghan
    Rafie, Carlin
    Regev, Arie
    Page, J. Bryan
    Berkman, Ronald
    Campa, Adriana
    JOURNAL OF ADDICTIVE DISEASES, 2008, 27 (02) : 37 - 48
  • [45] HIV/HCV co-infected patients experience HCV viral rebound after the second day of IFN treatment
    Mika, BP
    McCarthy, ME
    Layden, TJ
    Wiley, TE
    HEPATOLOGY, 1999, 30 (04) : 195A - 195A
  • [46] Optimizing Hepatitis C Therapy in HIV/HCV Co-Infected Patients: Analysis of HCV Viral Kinetics On Treatment
    James, Paul
    Wong, David K.
    Mazzulli, Tony
    GASTROENTEROLOGY, 2009, 136 (05) : A840 - A841
  • [47] Regression of Liver Stiffness after Successful HCV-Treatment and Associated Factors in HCV Mono-Infected and HCV-HIV Co-Infected Patients
    Malin, Jakob
    Boesecke, Christoph
    Schware-Zander, Carolynne
    Wasmuth, Jan Christian
    Schlabe, Stefan
    Trebicka, Jonel
    Spengler, Ulrich
    Llibre, Joseph Maria
    Jou, Toni
    Puig, Jordi
    Clotet, Bonaventura
    Rockstroh, Juergen Kurt
    HEPATOLOGY, 2018, 68 : 421A - 421A
  • [48] LOWER UPTAKE OF HCV TREATMENT THAN HIV TREATMENT IN HIV/HCV CO-INFECTED PATIENTS
    Stenkvist, J.
    Weiland, O.
    Sonnerborg, A.
    Blaxhult, A.
    Falconer, K.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S327 - S327
  • [49] High presence of HCV genotype 4d in HIV/HCV co-infected HIV / HCV patients in Espana.LOST G4
    Ortega Gonzalez, Enrique
    von Wichmann, Miguel A.
    Alma Bracho, Maria
    Asensi, Victor
    Antonio Mira, Jose
    Granados, Rafael
    Montes, Marisa
    Giner, Livia
    Martin, Carlos
    Rivero-Juarez, Antonio
    Arnaiz de las Revillas, Francisco
    Berenguer, Juan
    Tural, Cristina
    Vera, Francisco
    Luis Gomez-Sirvent, Juan
    Antonio Oteo, Jose
    Martinez, Elisa
    Aguilera, Antonio
    Morano, Luis
    Navarro, Jorge
    Oropesa, Roberto
    Moreno, Javier
    Rubio-Cuevas, Purificacion
    HEPATOLOGY, 2016, 64 : 408A - 409A
  • [50] HCV genotype profile in Brazil of mono-infected and HIV co-infected individuals: A survey representative of an entire country
    Rodrigues Nutini, Mariana Fernanda
    Hunter, James
    Giron, Leila
    Pinto Coelho Pires, Ana Flavia Nacif
    Kohiyama, Igor Massaki
    Camargo, Michelle
    Araripe Sucupira, Maria Cecilia
    Benzaken, Adele Schwartz
    Ferreira, Paulo Abrao
    Truong, Hong-Ha M.
    Diaz, Ricardo Sobhie
    PLOS ONE, 2020, 15 (01):